14 results on '"Vogler MA"'
Search Results
2. Clinical challenge. Severe headaches and cerebrovascular disease in a young man with perinatally acquired HIV infection.
- Author
-
Vogler MA and Ball SC
- Published
- 2008
3. Pregnancy in a perinatally infected woman: preventing second-generation mother-to-child transmission of HIV.
- Author
-
Vogler MA
- Published
- 2007
4. A new heterogeneous liver mass in a patient with well-controlled HIV and HBV infection.
- Author
-
Vogler MA
- Published
- 2006
5. COVID-19 in Hospitalized Adults With HIV.
- Author
-
Stoeckle K, Johnston CD, Jannat-Khah DP, Williams SC, Ellman TM, Vogler MA, Gulick RM, Glesby MJ, and Choi JJ
- Abstract
Background: The spread of SARS-CoV-2 and the COVID-19 pandemic have caused significant morbidity and mortality worldwide. The clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 and HIV co-infection remain uncertain., Methods: We conducted a matched retrospective cohort study of adults hospitalized with a COVID-19 illness in New York City between March 3, 2020, and May 15, 2020. We matched 30 people with HIV (PWH) with 90 control group patients without HIV based on age, sex, and race/ethnicity. Using electronic health record data, we compared demographic characteristics, clinical characteristics, and clinical outcomes between PWH and control patients., Results: In our study, the median age (interquartile range) was 60.5 (56.6-70.0) years, 20% were female, 30% were black, 27% were white, and 24% were of Hispanic/Latino/ethnicity. There were no significant differences between PWH and control patients in presenting symptoms, duration of symptoms before hospitalization, laboratory markers, or radiographic findings on chest x-ray. More patients without HIV required a higher level of supplemental oxygen on presentation than PWH. There were no differences in the need for invasive mechanical ventilation during hospitalization, length of stay, or in-hospital mortality., Conclusions: The clinical manifestations and outcomes of COVID-19 among patients with SARS-CoV-2 and HIV co-infection were not significantly different than patients without HIV co-infection. However, PWH were hospitalized with less severe hypoxemia, a finding that warrants further investigation., (© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2020
- Full Text
- View/download PDF
6. Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.
- Author
-
Vogler MA, Smeaton LM, Wright RL, Cardoso SW, Sanchez J, Infante R, Moran LE, Godfrey C, Demeter LM, and Johnson VA
- Subjects
- Adenine analogs & derivatives, Adenine therapeutic use, Adult, Alkynes, Benzoxazines therapeutic use, CD4 Lymphocyte Count, Cyclopropanes, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Emtricitabine, Female, HIV-1 isolation & purification, Humans, Organophosphonates therapeutic use, Pregnancy, Prospective Studies, RNA, Viral blood, Tenofovir, Treatment Outcome, Viral Load, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, HIV Infections drug therapy
- Abstract
Background: Women with HIV and prior exposure to combination antiretroviral therapy (cART) solely for prevention of mother-to-child transmission (pMTCT) need to know whether they can later be treated successfully with a commonly used regimen of efavirenz (EFV) and coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)., Methods: Nonpregnant women with plasma HIV-1 RNA of ≥500 copies per milliliter, previously cART exposed for pMTCT only, were eligible if they were off ART for ≥24 weeks before entry, were without evidence of drug resistance on standard genotyping, and were ready to start EFV plus FTC/TDF. The primary endpoint was virologic response (defined as plasma HIV RNA <400 copies/mL) at 24 weeks., Results: Fifty-four women were enrolled between October 2007 and December 2009; 52 of 54 completed 24 weeks of follow-up. Median baseline CD4 T-cell count was 265/mm and baseline plasma HIV-1 RNA was 4.6 log10 copies per milliliter. Median prior cART duration was 14 weeks, and median time elapsed from the last pMTCT dose to entry was 22 months. Virologic response at 24 weeks was observed in 42 of 52 women or 81% (exact 95% confidence interval: 68% to 90%). There were no differences in response by country, by number, or class of prior pMTCT exposures. Although confirmed virologic failure occurred in 8 women, no virologic failures were observed in women reporting perfect early adherence., Conclusions: In this first prospective clinical trial studying combination antiretroviral retreatment in women with a history of pregnancy-limited cART, the observed virologic response to TDF/FTC and EFV at 24 weeks was 81%. Virologic failures occurred and correlated with self-reported nonadherence.
- Published
- 2014
- Full Text
- View/download PDF
7. Complex decisions in managing HIV infection during pregnancy.
- Author
-
Vogler MA, Singh H, and Wright R
- Subjects
- Female, Humans, Infectious Disease Transmission, Vertical, Pregnancy, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, Pregnancy Complications, Infectious drug therapy
- Abstract
Both the World Health Organization and the United States Department of Health and Human Services have recently substantially revised perinatal HIV treatment guidelines based on emerging data, much of it from the developing world. Management of HIV infection in pregnancy and delivery is complicated by concerns for maternal and fetal drug toxicity, acquisition of antiretroviral resistance, prior therapy, co-infections with other viruses, as well as incident opportunistic infections. Intrapartum and peripartum obstetric management, including the role of Caesarean section, continue to evolve in the setting of maternal HIV infection. Finally, new data have expanded the role of antiviral therapy in allowing safer infant feeding choices for HIV-infected mothers in resource-limited settings.
- Published
- 2011
- Full Text
- View/download PDF
8. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
- Author
-
Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, and Cohn SE
- Subjects
- Adolescent, Adult, Contraceptives, Oral, Combined administration & dosage, Drug Combinations, Drug Interactions, Estrogens administration & dosage, Ethinyl Estradiol administration & dosage, Female, Humans, Lopinavir, Middle Aged, Norgestrel administration & dosage, Norgestrel pharmacokinetics, Oximes administration & dosage, Oximes pharmacokinetics, Pyrimidinones administration & dosage, Ritonavir administration & dosage, Transdermal Patch, United States, Contraceptives, Oral, Combined pharmacokinetics, Estrogens pharmacokinetics, Ethinyl Estradiol pharmacokinetics, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, HIV-1, Norgestrel analogs & derivatives, Pyrimidinones pharmacokinetics, Ritonavir pharmacokinetics
- Abstract
Background: Pharmacokinetic (PK) interactions between lopinavir/ritonavir (LPV/r) and transdermally delivered ethinyl estradiol (EE) and norelgestromin (NGMN) are unknown., Methods: Using a standard noncompartmental PK analysis, we compared EE area under the time-concentration curve (AUC) and NGMN AUC during transdermal contraceptive patch administration in HIV-1-infected women on stable LPV/r to a control group of women not on highly active antiretroviral therapy (HAART). In addition, EE AUC after a single dose of a combination oral contraceptive pill including EE and norethindrone was measured before patch placement and was compared with patch EE AUC in both groups. Contraceptive effects on LPV/r PKs were estimated by measuring LPV/r AUC at baseline and during week 3 of patch administration., Results: Eight women on LPV/r, and 24 women in the control group were enrolled. Patch EE median AUC0-168 h was 45% lower at 6010.36 pg·h·mL in those on LPV/r versus 10911.42 pg·h·mL in those on no HAART (P = 0.064). Pill EE median AUC0-48 hours was similarly 55% lower at 344.67 pg·h·mL in those on LPV/r versus 765.38 pg·h·mL in those on no HAART (P = 0.003). Patch NGMN AUC0-168 h however, was 138.39 ng·h·mL, 83% higher in the LPV/r group compared with the control AUC of 75.63 ng·h·mL (P = 0.036). After 3 weeks on the patch, LPV AUC0-8 h decreased by 19%, (P = 0.156)., Conclusions: Although PKs of contraceptive EE and NGMN are significantly altered with LPV/r, the contraceptive efficacy of the patch is likely to be maintained. Larger studies are indicated to fully assess contraceptive efficacy versus risks of the transdermal contraceptive patch when co-administered with protease inhibitors.
- Published
- 2010
- Full Text
- View/download PDF
9. Severe headaches and cerebrovascular disease in a young man with perinatally acquired HIV infection.
- Author
-
Vogler MA
- Subjects
- Adult, Brain diagnostic imaging, HIV Infections drug therapy, Hospitalization, Humans, Magnetic Resonance Imaging, Male, Radiography, Thoracic, Tomography, Emission-Computed, Cerebrovascular Disorders etiology, HIV Infections complications, Headache etiology
- Published
- 2008
10. Update: preventing mother-to-child transmission of HIV.
- Author
-
Vogler MA
- Subjects
- Breast Feeding, Female, HIV Infections diagnosis, HIV-1, Humans, Infant, Newborn, Pregnancy, Anti-HIV Agents therapeutic use, HIV Infections prevention & control, HIV Infections transmission, Infectious Disease Transmission, Vertical prevention & control, Pregnancy Complications, Infectious drug therapy
- Abstract
The success of antiretroviral therapies for prevention of mother-to-child transmission of HIV in the developed world has prompted a wide array of research efforts, from improved implementation of voluntary counseling and testing programs to innovative approaches for short-course peripartum prophylaxis to understanding the dynamics of HIV transmission via breastfeeding. Clinical trials of modified short-course peripartum regimens which are applicable to resource-limited areas are demonstrating much lower transmission rates and preliminary data are emerging on limiting transmission via breastfeeding. Some of the most recent data on these topics are reviewed. Primary prevention of HIV in women of childbearing age combined with efforts to prevent mother-to-child transmission of HIV offer the best hope for addressing the burden of HIV in women and children.
- Published
- 2006
- Full Text
- View/download PDF
11. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
- Author
-
Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, and Schock B
- Subjects
- AIDS Vaccines, Adult, Aged, Drug Therapy, Combination, Female, HIV Infections immunology, HIV-1, Humans, Interleukin-2 administration & dosage, Male, Middle Aged, RNA, Viral blood, Viral Load, Anti-HIV Agents administration & dosage, CD4 Lymphocyte Count, HIV Infections drug therapy, Interleukin-2 therapeutic use
- Abstract
Context: Approaches to preserve or enhance immune function in HIV-1 infection are needed., Objectives: To examine the ability of daily low-dose interleukin-2 (IL-2) in combination with antiretroviral therapy to preserve circulating CD4+ T-cell counts, the clinical safety and tolerability of this treatment, and safety with respect to changes in plasma HIV-1 RNA levels., Design: Twenty-four-week, phase 2, multicenter, randomized, open-label trial conducted at 12 AIDS Clinical Trials Units between September 1995 and May 1997., Participants: A total of 115 HIV-infected persons with screening CD4+ T-cell counts between 300 and 700 cells/mm who were on stable single- or dual-nucleoside therapy for at least 2 months, 11% of whom were also on a protease inhibitor at study entry., Interventions: Patients were randomly assigned to receive IL-2 at a dose of 1 million IU subcutaneously once daily plus continued anti-retroviral therapy (ART + IL-2, n = 57) vs. continued ART alone (ART alone, n = 58). IL-2 dose reductions were made for objective or subjective toxicities. All subjects randomly assigned to the IL-2 arm who interrupted ART were also required to discontinue IL-2 for the same period., Main Outcome Measures: The primary endpoint was a decrease in CD4 T-cell count from baseline; the safety analysis was based on change in plasma HIV RNA by bDNA; and clinical safety and tolerability were analyzed by standard clinical criteria., Results: Of the patients with a baseline CD4 T-cell count recorded, 15 (27%) of 55 patients randomly assigned to ART alone had a drop of > or =25% in their CD4 T-cell count and 23 (41%) of 56 patients randomly assigned to ART + IL-2 had a drop of > or =25% in their CD4 T-cell count at some time over the 24 weeks of the study. This difference was not statistically significant. There was a statistically significant greater variance in CD4 T-cell counts in the IL-2-treated group. More patients in the IL-2 group had at least a 25% increase in CD4 T-cell counts over baseline (34 vs. 13%, P = 0.007). A comparison of grade 3 or worse toxicity showed no differences between the arms, but IL-2 was associated with significantly more grade 2 or worse general body symptoms, primarily discomfort and fatigue. There was no significant difference between the groups with regard to changes in plasma HIV RNA, lymphocyte proliferation, natural killer cell activity, skin test responses to recall antigens, or antibody responses to immunization. Plasma markers of immune activation all increased significantly in IL-2 recipients., Conclusions: In patients with baseline CD4 T-cell counts > or =300 cells/mm primarily treated with single- or dual-nucleoside ART, subcutaneously administered IL-2 at a dose of 1 million IU daily for up to 24 weeks had low toxicity but showed no consistent benefit in preventing decline in CD4 T-cell counts and minimal evidence of immunologic improvement vs. continued ART alone.
- Published
- 2004
- Full Text
- View/download PDF
12. The use of cultured rat embryos to evaluate the teratogenic activity of serum: cadmium and cyclophosphamide.
- Author
-
Klein NW, Vogler MA, Chatot CL, and Pierro LJ
- Subjects
- Animals, Cadmium blood, Cell Survival, Cells, Cultured, Cyclophosphamide blood, DNA metabolism, Embryo, Mammalian metabolism, Proteins metabolism, Rats metabolism, Time Factors, Cadmium pharmacology, Culture Media pharmacology, Cyclophosphamide pharmacology, Rats embryology
- Abstract
Head fold stage rat embryos were cultured for 48 hours in vitro on serum taken at various intervals from rats that had been injected ip with either cadmium or cyclophosphamide. Their response was compared to that of embryos cultured for the same period on control serum to which these substances were added directly. One and 4 hour sera from cadmium-injected rats (2.13 mgCd++/kg) were lethal. Eight hour serum allowed survival but embryos were exencephalic and contained reduced amounts of protein and DNA. The response to direct cadmium was characteristically different and was related to dosage and the extent to which zero-time embryos had progressed through the head fold stage. At 1.6 micro M, Cd++ susceptible embryos were hemorrhagic, though not exencephalic. One hour serum from rats given cyclophosphamide (180 mg/kg) was lethal. On 4 hour serum, embryos survived but were exencephalic and contained less protein and DNA than controls. Embryos were resistant to direct cyclophosphamide up to 800 micrograms per ml of medium. At this concentration, embryos appeared morphologically normal but contained reduced amounts of protein.
- Published
- 1980
- Full Text
- View/download PDF
13. Clearance of 99mTc-diisopropyl-IDA in the "steady state".
- Author
-
Karimeddini MK, Vogler MA, and Spencer RP
- Subjects
- Abdomen diagnostic imaging, Aged, Drainage methods, Humans, Liver metabolism, Male, Radionuclide Imaging, Technetium Tc 99m Disofenin, Cholestasis, Extrahepatic diagnostic imaging, Imino Acids, Liver diagnostic imaging, Technetium
- Abstract
A 77-year-old man with a stent in place for biliary drainage was examined. Intravenously administered 99mTc-diisopropyl-IDA showed little accumulation of activity in the abdomen while the stent was draining internally. Upon switching the stent to external drainage, it was possible to monitor the slow movement of the bile which contained radioactivity. Imaging over the liver and comparing activity changes with a 99mTc standard showed that the decrease in hepatic radioactivity was identical to that occurring in the 99mTc standard. The liver was thus in a "steady state" for excretion of the 99mTc hepatobiliary agent, for it was extracting as much radioactivity from the circulation as it was excreting.
- Published
- 1984
- Full Text
- View/download PDF
14. Serum protein depletion by cultured rat embryos (1).
- Author
-
Klein NW, Minghetti PP, Jackson SK, and Vogler MA
- Subjects
- Animals, Blood Proteins isolation & purification, Centrifugation, Culture Media, Female, In Vitro Techniques, Male, Molecular Weight, Rats, Blood Proteins metabolism, Embryo, Mammalian metabolism
- Abstract
Cultures of 10-day rat embryos depleted a protein band with a molecular weight of approximately 125,000 from the rat serum medium. Delayed centrifuged serum differed from immediately centrifuged serum by a reduction in the staining intensity of the 125,000 molecular weight protein band and by the absence of two high molecular weight (greater than 200,000) protein bands.
- Published
- 1978
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.